Biotechnology and Bioprocess Engineering 2022; 27(3): 407-414  
Attenuation of Psoriasis Symptoms Following Treatment with C-phycocyanin from Spirulina Maxima in a Mouse Model
Jin Young Jang, Byung Man Lee, Sang Yoon Jun, Yun Jung Yang, and Hwa Sung Shin
Jin Young Jang, Byung Man Lee, Sang Yoon Jun, Yun Jung Yang, Hwa Sung Shin*
Department of Biological Engineering, Inha University, Incheon 22212, Korea
Tel: +82-32-860-9221; Fax: +82-32-872-4046
E-mail: hsshin@inha.ac.kr
Jin Young Jang and Byung Man Lee equally contributed to this work.
Received: January 20, 2022; Accepted: February 2, 2022; Published online: June 30, 2022.
© The Korean Society for Biotechnology and Bioengineering. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Psoriasis is a chronic autoimmune disease caused by an abnormal proliferation of keratinocytes in the epidermis. The efficacy of C-Phycocyanin, a photosynthetic pigment isolated from Spirulina Maxima, was assessed via histological examinations, and anti-inflammatory properties were investigated in mouse models of imiquimod-induced psoriasis (BALB/C-nu and BALB/C). C-phycocyanin lowered epidermal thickening, as well as immune cell clustering in the dermis. Furthermore, C-phycocyanin modulated the levels of inflammatory cytokines (tumor necrosis factor-α, interleukin [IL]-6, cyclooxygenase-2, IL-1b) in the BALB/C-nu mouse model and psoriasis-related cytokines (IL-17a, interferon-gamma, calcitonin gene-related peptide) in BALB/ c mice. We show that C-phycocyanin could be developed as a natural pharmaceutical against psoriasis.
Keywords: psoriasis, C-phycocyanin, Spirulina Maxima, animal test, anti-inflammation


This Article


Cited By Articles
  • CrossRef (0)

Services
Social Network Service

Archives